Abstract
Background: We describe the case of an 11-year-old boy affected by chronic granulomatous disease complicated by a Crohn’s like colitis needing prolonged treatment with oral corticosteroids.
Case Presentation: His therapy for the control of severe oral mucositis was based on topical clobetasol, which did not decrease once the steroids were discontinued. Two years after the oral interruption of the steroids, cushingoid characteristics persisted, the cause of which, after a thorough investigation, was found to be the persistence of the topical clobetasol oral gel.
Conclusion: Several studies investigated the efficacy of topical clobetasol for immuno-related mucositis, but little is known about its pharmacokinetics and side effects. In this report, we have reviewed the literature, defining a maximum putative dose of clobetasol mucosal gel to avoid Cushing syndrome.
Keywords: clobetasol, iatrogenic, cushingoid, adrenal suppression, cushingoid syndrome, mucositis, case report.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Topical Clobetasol: An Overlooked Cause of Cushing Syndrome
Volume: 21 Issue: 12
Author(s): Sergio Ghirardo, Laura De Nardi, Alberto Tommasini, Egidio Barbi and Gianluca Tornese*
Affiliation:
- Institute for maternal and child health IRCCS ‘Burlo Garofolo’, Trieste,Italy
Keywords: clobetasol, iatrogenic, cushingoid, adrenal suppression, cushingoid syndrome, mucositis, case report.
Abstract:
Background: We describe the case of an 11-year-old boy affected by chronic granulomatous disease complicated by a Crohn’s like colitis needing prolonged treatment with oral corticosteroids.
Case Presentation: His therapy for the control of severe oral mucositis was based on topical clobetasol, which did not decrease once the steroids were discontinued. Two years after the oral interruption of the steroids, cushingoid characteristics persisted, the cause of which, after a thorough investigation, was found to be the persistence of the topical clobetasol oral gel.
Conclusion: Several studies investigated the efficacy of topical clobetasol for immuno-related mucositis, but little is known about its pharmacokinetics and side effects. In this report, we have reviewed the literature, defining a maximum putative dose of clobetasol mucosal gel to avoid Cushing syndrome.
Export Options
About this article
Cite this article as:
Ghirardo Sergio , De Nardi Laura , Tommasini Alberto , Barbi Egidio and Tornese Gianluca *, Topical Clobetasol: An Overlooked Cause of Cushing Syndrome, Endocrine, Metabolic & Immune Disorders - Drug Targets 2021; 21 (12) . https://dx.doi.org/10.2174/1871530321666210426131423
DOI https://dx.doi.org/10.2174/1871530321666210426131423 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Systemic DNA Damage Response and Metabolic Syndrome as a Premalignant State
Current Molecular Medicine How to Assess Sympathetic Nervous System Activity in Clinical Practice
Current Clinical Pharmacology Is there a Role for Bevacizumab in Non-Glial Tumors?
Current Drug Targets A Murine Model of Vasculitis Induced by Fungal Polysaccharide
Cardiovascular & Hematological Agents in Medicinal Chemistry Human Papilloma Virus Vaccine Associated Uveitis
Current Drug Safety Organic Cation Transporters: Physiology, Toxicology and Special Focus on Ethidium as a Novel Substrate
Current Drug Metabolism Potential Linkage Between Cerebrovascular Diseases and Metabolic Syndrome
Current Drug Metabolism Genome-Wide Association Studies: Is there a Genotype for Cognitive Decline in Older Persons with Type 2 Diabetes?
Current Pharmaceutical Design The Role of Novel Biomarkers of Cardiovascular Disease in Chronic Kidney Disease: Focus on Adiponectin and Leptin
Current Cardiology Reviews Long-term Outcomes of Cerebral Venous Sinus Stenosis Corrected by Stenting
Current Neurovascular Research Pharmacological and Surgical Therapy for Primary Postpartum Hemorrhage
Current Pharmaceutical Design Novel Approaches to Target Pancreatic Cancer
Current Cancer Drug Targets Editorial
Current Medical Imaging The Potential Role of Serum Exosomes in Preeclampsia
Current Drug Metabolism Does Daily Dialysis Improve Hypertension in Chronic Haemodialysis Patients?
Current Hypertension Reviews Infection and Malignancy Risk in Patients Treated with TNF Inhibitors for Immune-Mediated Inflammatory Diseases
Current Drug Safety Brain Excitatory/Inhibitory Circuits Cross-Talking with Chromogranin A During Hypertensive and Hibernating States
Current Medicinal Chemistry Bioactivity of American Ginseng by Knockout Extract Preparation Using Monoclonal Antibody
Current Drug Discovery Technologies Can Lipoprotein-associated Phospholipase A<sub>2</sub> be Used as a Predictor of Long-term Outcome in Patients with Acute Coronary Syndrome?
Current Cardiology Reviews Fetal Protein Restriction, Taurine and Islet Plasticity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)